Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating that Sangamo's common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq's minimum bid price requirement. Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination. The hearing will not stay the suspension of trading of Sangamo's common stock, and trading of Sangamo's common stock on The Nasdaq Capital Market is expected to be suspended at the open of trading on May 5, 2026.